213 related articles for article (PubMed ID: 12271501)
41. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
42. Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab.
Herold M; Dölken G; Fiedler F; Franke A; Freund M; Helbig W; Pasold R
Ann Hematol; 2003 Feb; 82(2):77-9. PubMed ID: 12601483
[No Abstract] [Full Text] [Related]
43. Optimizing rituximab in B-cell lymphoma.
Horning SJ
J Clin Oncol; 2005 Feb; 23(6):1056-8. PubMed ID: 15657408
[No Abstract] [Full Text] [Related]
44. Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab.
Vallet S; Tempescul A; Tran A; Legrand-Quillien MC; Narbonne V; Berthou C
Ann Hematol; 2005 Aug; 84(8):545-7. PubMed ID: 15789227
[No Abstract] [Full Text] [Related]
45. Successful treatment of focal segmental glomerulosclerosis in association with mantle cell lymphoma.
Wong CF; Mohteshamzadeh M; Arsalanizadeh B; Dutt T; Shawki H; Khine MM; Rustom R
Ren Fail; 2007; 29(3):363-6. PubMed ID: 17497453
[No Abstract] [Full Text] [Related]
46. Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival.
Turturro F
Expert Rev Anticancer Ther; 2007 Jul; 7(7):959-65. PubMed ID: 17627454
[TBL] [Abstract][Full Text] [Related]
47. Third biannual report of the Cochrane Haematological Malignancies Group.
Kober T; Skoetz N; Trelle S; Bohlius J; Engert A;
J Natl Cancer Inst; 2005 Aug; 97(16):E2. PubMed ID: 16106014
[No Abstract] [Full Text] [Related]
48. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
Kanaji N; Ishibashi K; Uno H; Hino N
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
[TBL] [Abstract][Full Text] [Related]
49. Current status of rituximab maintenance therapy.
Vose JM
Clin Adv Hematol Oncol; 2007 Dec; 5(12):968-9,1006. PubMed ID: 18277958
[No Abstract] [Full Text] [Related]
50. Rituximab for follicular non-Hodgkin lymphoma.
Gajraj E; Chung H; Longson C; Stevens A
Lancet Oncol; 2008 Apr; 9(4):320-1. PubMed ID: 18405852
[No Abstract] [Full Text] [Related]
51. [Disappearance of CD 20 after treatment with rituximab of mantle cell lymphoma].
Yoshida K; Kayano H; Shimada T; Wakao D; Takahashi N; Sugahara Y; Yagasaki F; Ito Y; Kawai N; Matsuda A; Suzuki T; Bessho M
Rinsho Ketsueki; 2003 Mar; 44(3):174-81. PubMed ID: 12722344
[TBL] [Abstract][Full Text] [Related]
52. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
[TBL] [Abstract][Full Text] [Related]
53. Rituximab for follicular lymphoma.
Maloney DG
Curr Hematol Rep; 2003 Jan; 2(1):13-22. PubMed ID: 12901150
[TBL] [Abstract][Full Text] [Related]
54. High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen.
Magni M; Di Nicola M; Carlo-Stella C; Matteucci P; Devizzi L; Tarella C; Benedetti F; Martelli M; Patti C; Parvis G; Rambaldi A; Barbui T; Gianni AM
Bone Marrow Transplant; 2009 Mar; 43(6):509-11. PubMed ID: 18955979
[No Abstract] [Full Text] [Related]
55. Rituximab: new indication. Lymphoma maintenance therapy: inadequate follow-up.
Prescrire Int; 2007 Oct; 16(91):189. PubMed ID: 17926825
[TBL] [Abstract][Full Text] [Related]
56. [Follicular lymphoma].
Illés A; Krenács L; Borbényi Z
Orv Hetil; 2003 Nov; 144(46):2253-61. PubMed ID: 14702920
[TBL] [Abstract][Full Text] [Related]
57. [Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].
Ogura M
Rinsho Ketsueki; 2008 Oct; 49(10):1434-50. PubMed ID: 18833928
[No Abstract] [Full Text] [Related]
58. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression.
Saito B; Shiozawa E; Yamochi-Onizuka T; Adachi D; Nakamaki T; Tomoyasu S; Omine M; Mitsuya T; Takimoto M; Ota H
Pathol Int; 2004 Sep; 54(9):667-74. PubMed ID: 15363034
[TBL] [Abstract][Full Text] [Related]
59. [Standard therapy and research questions in follicular lymphoma].
Ishizawa K
Rinsho Ketsueki; 2012 Oct; 53(10):1624-33. PubMed ID: 23037735
[No Abstract] [Full Text] [Related]
60. [Progressive multifocal leukoencephalopathy after rituximab therapy in a patient with mantle cell lymphoma].
Ota I; Katsura Y; Yoshida C; Yoshizawa K; Ohtani H; Sata T; Komeno T
Rinsho Ketsueki; 2010 Dec; 51(12):1786-8. PubMed ID: 21258190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
